- Home
- ATRA vs RLYB Comparison
ATRA vs RLYB Comparison
Compare ATRA & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | RLYB |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.2M | 86.6M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATRA | RLYB |
|---|---|---|
| Price | $9.00 | $16.98 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 44.7K | 15.7K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | ★ $120,772,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.72 |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $3.92 | $0.48 |
| 52 Week High | $19.15 | $17.57 |
Technical Indicators
Market Signals| Indicator | ATRA | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 55.71 |
| Support Level | $9.03 | $16.51 |
| Resistance Level | $11.17 | $17.34 |
| Average True Range (ATR) | 0.66 | 0.47 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 62.01 | 47.32 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.